bluuebunny/crossref_metadata_2025 huggingface dataset:
Sinus rhythm endocardial mapping for channels identification in ischemic ventricular tachycardia using a modified electrophysiological triad
Authors: Adragao P , Nascimento Matos D , Galvao Santos P , Costa F , Rodrigues G , Carmo J , Salome Carvalho M , Carmo P , Morgado F , Cavaco D , Mendes M
Published: October 2022

Background

In a previous study it was demonstrated that an electrophysiological triad was able to identify critical isthmus in atrial flutter (AFL) patients. This triad is based in the Carto® electroanatomical mapping (EAM) version 7, which displays a histogram of the local activation times (LAT) of the tachycardia cycle length (TCL), in addition to the activation and voltage maps.

Purpose

This study aimed to prospectively assess the ability of a modified electrophysiological triad to identify and localize the ventricular tachycardia's (VT) channels and entrance zones during sinus rhythm mapping.

Methods

Prospective analysis of a unicentric registry of individuals who underwent ischemic VT ablation with Carto® EAM, all in sinus rhythm. All patients with non-ischemic etiology, lack of high-density EAM or lack of mapping in any of the left ventricle walls or structures were excluded. Areas of late potentials and possible channels of re-entry were compared to a modified electrophysiological triad constituted by: areas of low-voltage (<0.5mV), a site of deep histogram valley (LAT-Valley) with less than 20% density points relative to the highest density zone and a prolonged LAT-Valley duration that included 10% or more of the total activation time mapped. We also assessed the relationship between the pre-valley bar (the LAT histogram bar immediately before the prolonged LAT-Valley) and the channel entrances.

Results

A total of 14 patients (14 men, median age 70 IQR 64–78 years) were included. All patients presented with ischemic VT and 86% had a previous inferior myocardial infarction. The median number of collected points were 1733 (IQR 1363–2729). All sinus rhythm maps presented with at least 1 LAT-Valley in the analysed histograms. All arrhythmias were effectively treated after undergoing radiofrequency in the LAT-Valley location, either by blocking the channel entrances or scar homogenization ablation strategy. Also, the pre-valley bar in the histogram marked all the channel entrances in the scar borders. No patient had relapse after a clinical follow up of over 6 months.

Conclusion

In a prospective analysis, a modified electrophysiological triad was able to identify the scar channels in sinus rhythm in all patients. The pre-valley bar in the histogram disclosed the channel entrances. Further studies are needed to assess the usefulness of this algorithm to simplify catheter ablation and improve clinical outcomes.

Funding Acknowledgement

Type of funding sources: None.
Assessing outcomes following catheter ablation of ventricular tachycardia in patients with durable left ventricular assist devices
Authors: Olarte N , Vincent L , Ebner B , Grant J , Maning J , Hernandez R , Rivera-Rodriguez B , Giraldo M , Grazette L
Published: October 2022

Background

Management of ventricular tachycardia (VT) after implant of a durable left ventricular assist device (LVAD) is challenging, without consensus on optimal therapy. Multiple small studies have examined catheter ablation of VT in these patients with low reported incidence of complications.

Purpose

We sought to evaluate periprocedural outcomes following VT ablation among LVAD recipients.

Methods

We queried the National Inpatient Sample from 2011 to 2019 to conduct our study. Baseline characteristics include age, sex, race, and comorbidities related to cardiovascular disease. Comorbidity severity was assessed using the Deyo-Charlson Comorbidity Index (Deyo-CCI). Patients with any supraventricular arrhythmias were excluded. Outcomes investigated include heart transplant procedure, all-cause mortality, major adverse cardiovascular events (MACE), and periprocedural complications. Multivariate regression was used to analyze outcomes associations adjusted for baseline characteristics that were significantly different (P<0.05) between cohorts expressed as adjusted odds ratios (aOR) and 95% confidence intervals (CI). SPSS v28.0 (IBM, Armonk, NY) was used to carry out all calculations.

Results

We identified 56 patients who underwent ablation among 2,202 LVAD recipients hospitalized for VT. Patients who underwent ablation were more likely to have ischemic cardiomyopathy (33.9% vs. 22.2%, p=0.03) or an automated implantable cardioverter-defibrillator (55.4% vs 34.3%, p=0.001). There were otherwise no significant differences between cohorts (mean Deyo-CCI score of 2.3 for both, p=0.48). Between those who did and did not undergo ablation, there were no significant differences in heart transplant (5.4 vs 5.0%, p=0.9), mortality (7.1% vs 7.0%, p=0.96), total strokes (3.6% vs 5.0%, p=0.48), myocardial infarction (3.6% vs 4.6%, p=0.71), overall MACE (8.9% vs 10.2%, p=0.26) or total complications (35.7% vs 41.9%, p=0.35). There were no incidents of pump thrombosis in the ablation group, but 92 events (4.3%) were found in the medical therapy group. Multivariate analysis affirmed no significant association between ablation and mortality (aOR 1.277, CI [0.450–3.629]), MACE (aOR 1.125, CI [0.436–2.902]), or total complications (aOR 0.932, CI [0.528–1.645]).

Conclusion

Overall complications following VT ablation among LVAD patients were higher than previously reported but no statistically significant differences were found compared to conservative management. While ablation appears safe to perform, particularly among those with structural heart disease and ischemic cardiomyopathy, longer duration studies are needed to determine the efficacy of this procedure.

Funding Acknowledgement

Type of funding sources: None.
Ventricular tachycardia mechanisms and prevention in patients with severe heart failure and left ventricular assist device
Authors: Hohendanner F , Bock M , Keznickl J , Scholz S , Potapov E , Pieske B , Gerds-Li J H
Published: October 2022

Terminal Heart Failure with reduced Ejection Fraction (HFrEF) is associated with severe morbidity and mortality. Mechanical Left Ventricular Assist Devices (LVAD) are often used to provide these patients with a last resort therapy and as bridge to transplant. However, HFrEF patients with LVAD have significant myocardial substrate for ventricular arrhythmias and the LVAD itself might be regarded as pro-arrhythmogenic. Aim of the current study was to investigate the mechanism of ventricular arrhythmias in LVAD patients and to provide evidence for the hypothesis that ad-hoc ablation/substrate modification during surgical LVAD implantation might reduce the risk of VT.

We retrospectively analyzed invasive ablation procedures in patients with VT±LVAD and determined the mechanism of arrhythmia during electrophysiological examination (using 3D electroanatomical and local activation time mapping; Carto; Biosense Webster) in LVAD (n=17) and non-LVAD (n=12) subgroups. Mean age of the predominantly male (97%) patients was 60±2 years. VTs were directly LVAD associated (i.e. focal, adjacent to LVAD insertion or macro-reentry, around LVAD) in almost half of the LVAD patients. Number of radiofrequency ablation (RF) lesions and RF time were not significantly different between LVAD associated VT and non-LVAD associated VT patients. Within the LVAD patient group, freedom from VT (mean follow-up 40±6 months) was 50% upon ablation in patients with VTs originating from the LVAD region and 70% if ablation was conducted in non-LVAD regions. None of the LVAD associated and 22% of non-LVAD associated VT patients died during follow-up of these critically ill patients. Moreover, to reduce LVAD related arrhythmias and based on additional ex-vivo/in-silico derived data, we propose a distinctive (i.e. “star” shaped, LVAD encirclement) epicardial substrate modification during surgical LVAD implantation.

In summary, a significant percentage of patients with LVAD exhibit LVAD-associated focal/macro-reentry VT and recurrence rates are high. VT likelihood is reduced ex-vivo/in-silico upon substrate modification targeting myocardium adjacent to a possible LVAD implantation site. Epicardial RF ablation during surgical LVAD implantation might allow prevention of LVAD-associated focal/macro-reentry VT.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): DFG
Cardiac radioablation does not worsen cardiac function: preliminary safety results of the prospective STARNL-1 trial
Authors: Hoeksema W , Van Der Ree M H , De Bruin-Bon H A C M , Dieleman E M T , Visser J , Planken R N , Boekholdt S M , De Jong M A J , Kemme M J B , Balt J C , Balgobind B V , Postema P G
Published: October 2022

Background

Cardiac radioablation for ventricular tachycardia (VT) appears to be highly effective and safe in patients with recurrent VT despite anti-arrhythmic therapy and catheter ablation(s), although global experience is currently very limited. Detailed echocardiographic strain analysis could provide important insights in (subclinical) functional safety. Importantly, current stereotactic cardiac radioablation techniques includes irradiation of the VT substrate but, inherently, also includes irradiation of the VT border zone and some healthy cardiac tissue. The latter particularly may result in detoriation of cardiac function after cardiac radioablation.

Purpose

To evaluate functional echocardiographic safety of cardiac radioablation.

Methods

The STARNL-1 trial is a prospective, monocenter, single-arm, pre-post intervention study. Six patients with recurrent VT despite high dose anti-arrhythmic drugs, after (single or multiple) conventional catheter ablation and deemed unsuited for repeat catheter ablation, were treated with a single fraction 25 Gy radiotherapy dose. Per protocol, patients underwent echocardiograms at baseline, 24 hours after treatment, and 3 months after treatment. Echocardiograms were analysed using 2D-speckle tracking. Mean radiotherapy dose per segment was calculated according to the AHA 17-segment model. Echocardiographic parameters were compared between baseline, 24 hours and 3 months, and correlated to radiotherapy dose.

Results

Patients were all male (age 55–83 years), all suffered from ischaemic cardiomyopathy, and all completed 3 month follow-up. At baseline, median left ventricle ejection fraction (LVEF) was 38% [30; 47] and median global longitudinal strain (GLS) −8% [−12; −5]. Interestingly, LVEF significantly improved 24 hours after treatment (42% [36; 49], p=0.046) but GLS did not change (−7% [−12; −5], p=0.833). At 3 months, both LVEF and GLS were unchanged compared to baseline (LVEF 39% [33; 49%], p=0.463; GLS −6% [−12; −5], p=0.893). The difference in longitudinal strain per segment before and after treatment did not correlate with the mean radiotherapy dose per segment, both 24 hours after treatment (Pearson coefficient −0.082, p=0.410) and 3 months after treatment (Pearson coefficient −0.005, p=0.957). In Figure 1 an illustrative case is presented.

Conclusion(s)

Cardiac radioablation for VT does not worsen (subclinical) cardiac function within the first 3 months after treatment.

Funding Acknowledgement

Type of funding sources: Foundation. Main funding source(s): Dutch Heart Foundation
Physiological vs. non-physiological heart pacing as assessed by ultra-high-frequency ECG
Authors: Curila K , Jurak P
Published: October 2022

Background

The dyssynchrony related to permanent cardiac pacing is the main reason for heart failure in some patients. Physiological pacing techniques as His bundle pacing (HBP), left bundle branch pacing (LBBP), and left ventricular myocardial septal pacing (LVSP) were shown to improve clinical outcomes in patients with pacemakers. Due to specific lead placement in the area close to conductive tissue, several different ventricular capture types are possible during them.

Method

We studied the effect of these pacing modalities on ventricular synchrony using ultra-high-frequency ECG (UHF-ECG), which is a novel tool for ventricular depolarization visualization. Several parameters of dyssynchrony were calculated and compared between studied ventricular capture types.

Results

We showed ventricular depolarization during nonselective HBP to be equivalent to selective HB pacing. Next, we demonstrated the nonselective HBP in the area below the tricuspid valve leads to the best interventricular synchrony from all other RV pacing locations. We also compared UHF-ECG-derived parameters of ventricular depolarization during HBP, LBBP, and LVSP, and we showed that both pacing types from the left septal area are less physiological than HBP. nsLBBP and sLBBP deteriorate interventricular dyssynchrony, and LVSP leads to less physiological left ventricular depolarization than HBP.

Conclusion

UHF-ECG is an effective tool that can be used in clinical practice to assess the electrical dyssynchrony caused by cardiac pacing. Furthermore, its real-time implementation allows recognizing between physiological vs. non-physiological pacing during an implant procedure.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Ministry of Health of the Czech Republic
Medium term survival in patients over ninety years-old undergoing pacemaker implantation
Authors: Zecchin M , Trevisan B , Bessi R , Baggio C , Salvatore L , Cappelletto C , Gregorio C , Bianco E , Carriere C , Longaro F , Zorzin-Fantasia A , Saitta M , Piccinin F , Dal Monte G , Sinagra G
Published: October 2022

Background

According to the Italian National Statistical Institute, the 12-month probability of survival in the general population between 90 and 94 years-old is 26%. Pacemaker (PM) implantation is often an urgent and necessary intervention, but in these patients the benefit in terms of quality and duration of life is unclear.

Purpose

To analyze characteristics, outcome and factors associated with survival in patients who had turned 90 at the time of PM implant.

Methods

All the PM implants performed in patients ≥90 from 1/1/2019 to 12/31/2020 were analyzed. Clinical parameters, device characteristics and follow-up data were extrapolated from the SuitEstensa Ebit reporting system; the exitus was verified by analyzing data from the Regional Health System.

Results

During the study interval, among the 554 patients undergoing PM implantation in our Center, 69 (12%) were ≥90 years-old (mean age 92±2 years, 46% male; complete/advanced AV block in 76%). Twenty-six (38%) patients had history of atrial fibrillation and 19 (28%) ischemic heart disease. A cardiological co-morbidity (excluding AF) was present in 23 patients (33%). Oncological, pneumological and neurological comorbidities were present in 12 (18%), 19 (28%) and 32 (46%) respectively. Renal impairment was present in 25 patients (36%). In 47 patients (68%) there were at least 2 co-morbidities. After implantation (single-chamber in 36, dual-chamber in 25 and VDD single-lead dual-chamber in 8 patients) complications occurred in 3 patients (2 pneumothorax and 1 lead dislodgment). Remote monitoring was activated in 57 patients (83%).

Within August 31st 2021 (mean follow-up 288±193 days) 24 patients died (35%, 219±241 days after implant). Five patients (19% of patients implanted in 2019) died within 12 months. No patients died for device malfunction. Three patients died because of COVID-19 pneumonia.

Renal dysfunction (Hazard Ratio-HR 8.05, p=0.002) and the presence of 2 or more co-morbidities (HR 6.03; p=0.015) were associated with a higher risk of death at univariate analysis; other significant variables were diabetes (HR 2.34; p=0.038), left ventricular ejection fraction (LVEF) (HR 0.70 for 5% variation; p=0.005), walking impairment (HR 2.99, p=0.006), the presence of oncological (HR 2.21; p=0.003), pneumological (HR 2.55; p=0.024) and neurological (HR 1.90, p=0.007) comorbidities. At multivariable analysis the only significant parameter associated with survival was LVEF (0.76 for 5% difference; p=0.043)

Conclusions

At our Center, patients ≥90 years-old undergo PM implantation mainly for advanced AVB. The good survival in the medium term, even better than expected in the general population, does not justify a too conservative attitude especially, but exclusively, in patients with less comorbidities.

Funding Acknowledgement

Type of funding sources: None.
A new window on subcutaneous ICD system performance: Z-lead impedance change over time in devices with and without extracellular matrix envelope use
Authors: Liu K , Stahl W K , Riebman J B , Speakman B , Wu J E , Elayi C S , Deering T F , Catanzaro J N
Published: October 2022

Background

Device impedance for subcutaneous ICDs (S-ICDs) may rise over time reflecting changes in tissue electrical conduction due to fibrosis from the natural foreign body response, increasing the risk of defibrillation failure. A biologic envelope optimized for S-ICDs may mitigate fibrosis and encourages angiogenesis around the device possibly decreasing impedance rise over time. The S-ICD system performs routine low-voltage Z-lead (LVZ) impedance testing (impedance between shocking coil and can) that may provide insight into the impedance changes on device functionality and efficacy over time.

Purpose

Explore early and late impedance changes over time in S-ICDs implanted with and without envelopes using periodic LVZ measurements.

Methods

30 patients received S-ICDs (15 with envelope) between 1/2017 and 3/2021, after excluding those with device complications, uncontrolled comorbidities, or recent cardiac surgery. Impedance data was recorded at initial implantation. LVZ impedance data was extracted from the wireless remote monitoring system, trended over 0–4 years post implant, and analyzed blinded to patient information.

Results

24 patients (12 envelope) had evaluable implant and chronic data sets. Baseline clinical characteristics were similar between groups. Impedance in general was higher in the envelope group at initial implantation (LVZ mean 89 Ω vs 74 Ω) and throughout the first year. Comparing envelope to no envelope, the initial average shock impedance was 87.3±30.50 vs 66.7±10.40, followed by an average low-V impedance drop of 29 Ω vs 17 Ω during the first month, with a recovery to 109 Ω vs 91 Ω at 30 months post implant. After 30 months, impedance trends demonstrated a modest linear increase up to 48 months in the no envelope group in comparison with a modest decrease in the envelope group (sample sizes too small to determine significance) (Figure 1).

Conclusion

The results demonstrate periodic LVZ testing in the S-ICD monitoring system can reliably trend changes in system impedance over time. Impedance measurements within the first 6–7 months (and most markedly within the first 3 months) appear to be transiently lower than the values seen after this timepoint suggesting that early impedance measurements may not predict steady-state impedance. Further studies are needed to explore the impact of envelope use and the S-ICD impedance changes beyond 30 months.

Funding Acknowledgement

Type of funding sources: None.
The case against premature treatment of heart failure patients with implantable cardioverter-defibrillators: results from an institutional registry
Authors: Prepolec I , Pasara V , Bogdanic J E , Nekic A , Putric Posavec J , Pezo Nikolic B , Matasic R , Krpan M , Lovric-Bencic M , Percin L , Puljevic M , Puljevic D , Milicic D , Velagic V
Published: October 2022

Introduction

Implantable cardioverter-defibrillators (ICD) are gold-standard therapy for primary prevention (PP) of sudden cardiac death (SCD) in patients with heart failure with reduced ejection fraction (HFrEF). According to relevant guidelines, ICDs should be implanted only after patients have been treated with revascularization procedures and/or optimal medical therapy (OMT) [1]. Due to perceived high risk of SCD and low chance of improvement some patients receive ICDs “too early” in the course of the disease [2].

Purpose

To investigate adherence to guidelines in our institution with emphasis on premature ICD implantation and early ICD activation.

Methods

We analysed all ICDs newly implanted for PP in patients with HFrEF in our institution between 2011 and 2017. Follow-up data was collected from hospital medical records.

Results

Total number of 307 ICDs were implanted during the analysed interval, 147 (47.9%) in ischemic cardiomyopathy (ICM) and 160 (52.1%) in non-ischemic dilated cardiomyopathy (DCM) patients. Only 57.8% of ICM patients have been treated with OMT at least 3 months before implantation. The proportion was similar in DCM patients (60.0%). However, DCM patients were more commonly implanted at the time of diagnosis (13.8% vs. 0.7% in ICM). It is worth noting that OMT was up-titrated after implantation in 35.2% of patients. In 9 cases patients were treated with ICDs less than 3 months after revascularization procedures or less than 6 weeks after STEMI (6 and 3 cases respectively). Follow-up data revealed that among all the patients who prematurely received an ICD, a device activated to deliver appropriate therapy within 3 months of implantation only in 1 ICM patient (0.7% of ICM patients). That patient had established ICM and was suffering from recurrent unexplained syncopes. One DCM patient with prematurely implanted ICD had early inappropriate ICD activation that was due to supraventricular tachycardia. Early ICD activations were generally uncommon even among patients who were treated according to guidelines (1 ICM and 1 DCM patient).

Conclusion

Results from our institutional ICD registry show that a significant number of patients with HFrEF received premature ICD implants before being treated with OMT. This is even more common in patients newly diagnosed with DCM. Our follow-up data suggests that early ICD activation is extremely rare in all comers and hardly ever happens in patients who received ICD immediately after diagnosis, revascularization or without 3 months of OMT. This data can help improve our future practice and encourage clinicians to follow relevant guidelines when faced with these important decisions.

Funding Acknowledgement

Type of funding sources: None.
Effect of defibrillator on long term all-cause mortality in patients with chronic kidney disease: an updated meta-analysis
Authors: Aslam F , Al-Sadawi M , Aleem S , Alsaiqali M , Almasry I , Singh A , Rashba E , Fan R
Published: October 2022

Background

The beneficial role of implantable defibrillator (ICD) in patients with chronic kidney disease (CKD) is less understood as this population is often not well represented in clinical trials.

Purpose

Evaluate the effect of ICD use in patients with CKD on long term outcomes.

Methods

Literature search was conducted for studies reporting the effect of ICD on all-cause mortality in patients with CKD, which is defined as glomerular filtration rate (GFR) <60 mL/min. The search was not restricted to time or publication status. The search included the following databases: Ovid MEDLINE, EMBASE, Scopus, Web of Science, Google Scholar, and EBSCO CINAHL. The minimum duration of follow-up required for inclusion was one year.

Results

The literature search identified 834 studies, of which 14 studies with 70,661 patients were included. Mean follow up was 39 months (12–81 months). For all patients with CKD, ICD was associated with lower all-cause mortality (log HR −0.247, SE 0.101, p=0.015); Heterogeneity: df=13 (P<0.01), I2=97.057; Test for overall effect: Z=−2.431 (Figure 1). When further stratified based on dialysis, CKD patients without the need for dialysis had favorable outcome (log HR −0.211, SE 0.095, p=0.026); Heterogeneity: df=6 (P<0.01), I2=70.146; Test for overall effect: Z=−2.225, whereas ICD implantation in CKD patients requiring dialysis was not associated with mortality benefit (log HR −0.262, SE 0.134, p=0.051) (Figure 2A, B).

Conclusion

ICD implantation is associated with mortality benefit in patients with CKD, but this association is not present for patients requiring dialysis.

Funding Acknowledgement

Type of funding sources: None.
Mechanical dyssynchrony, a novel marker to predict long-term survival in patients with cardiac resynchronization
Authors: Ahmed M A , Sohns C , Rudolph V , Dumitrescu D , Faber L , Fox H
Published: October 2022

Background

Cardiac resynchronization therapy (CRT) is an established therapy in patients with symptomatic heart failure with reduced left ventricular ejection fraction (LVEF <35%) (HFrEF) that have conduction disturbances as measured by prolonged QRS duration of >130 ms. Mechanical dyssynchrony (MD) in echocardiography has not proven benefit to determine CRT indication, but is hypothesized to be of predictive value. Both MD aspects of “apical rocking” (AR) but also “septal flash” (SF) have been shown to be a predictive value in short- and medium-term follow-up in CRT, but no trial has tested long-term effects yet.

Purpose

This study investigated the impact of AR and SF on long-term survival in CRT recipients.

Methods and results

425 HFrEF patients (mean age: 63.0±10.6 years, 72.3% male, 60.7% non-ischemic etiology) with ESC guideline-derived CRT indication have been implanted and additionally investigated for MD markers at baseline as well as after a 11.5±8.0 months follow-up including long-term survival. Herein AR and/or SF were identified in 307 (72,2%) participants at baseline. During follow-up both AR and/or SF disappeared in 256 (83.4%) patients through CRT use. The overall mean survival was 95.9±52.9 months. Univariable analysis showed beneficial survival for women over men (109.1±52.4 vs. 90.9±52.4 months; p<0.001). Moreover, younger (<60 years) patients profit more than older patients (110.6±53.7 vs. 88.6±51.1 months; p<0.001). Interestingly, patients with MD markers at baseline generally had an improved overall survival (106.2±52.0 vs. 68.9±45.4 months; p<0.001), and in addition to that we found the best survival in patients with disappeared over persisting mechanical dyssynchrony echocardiography parameters in CRT (111.6±51.2 vs. 79.7±47.6 months p<0.001). Multivariate analysis shows age and presence of MD at baseline to be powerful predictors for long-term survival in CRT HFrEF patients (Figures 1 and 2).

Conclusion

Novel echocardiography MD parameters before CRT implantation predict long-term survival. Moreover, long-term survival even further improves when AR and/or SF disappear through CRT in HFrEF. Our results encourage a prospective, randomized, controlled, multicenter trial to study clinical implementation of MD in CRT patients.

Funding Acknowledgement

Type of funding sources: None.
Electromechanical factors associated with response to cardiac resynchronization therapy
Authors: Jadczyk T , Maffessanti F , Wilczek J , Conte G , Caputo M L , Golba K S , Biernat J , Cybulska M , Caluori G , Regoli F , Krause R , Wojakowski W , Prinzen F W , Auricchio A
Published: October 2022

Background

Cardiac resynchronization therapy (CRT) is clinically proven in patients with heart failure (HF) and left bundle branch block (LBBB). However, approximately 30% of CRT individuals are non responsive to the therapy while factors affecting electromechanical coupling remain not fully understood.

Objective

To determine the optimal combination of electromechanical parameters associated with responsiveness to CRT.

Methods

Sixty-two patients with HF/LBBB underwent invasive anatomo-electromechanical mapping (AEMM) of the left ventricle using NOGA XP system (Biosense Webster), cardiac magnetic resonance (cMR), transthoracic echocardiography and 12-lead ECG. Remodeling was quantified based on the end-systolic volume (ΔESV) decrease at 6-month follow-up. Response to CRT was defined as ΔESV ≤−15%. QRS duration (QRSd) was measured from a surface ECG. Area strain was obtained from AEMM and used to calculate systolic stretch index (SSI) and total left ventricular mechanical time (TLVMT). Total left ventricular activation time (TLVAT) and transeptal time (TST) were derived from AEMM and ECG. Scar burden was evaluated from cMR late gadolinium enhancement imaging.

Results

Significant correlations were observed between ΔESV and TST (rho=0.42; responder: 50 [20–58] vs non-responder: 33 [8–44] ms), TLVAT (−0.68; 81 [73–97] vs 112 [96–127] ms), scar burden (−0.27; 0.0 [0.0–1.2] vs 8.7 [0.0 19.1]%) and SSI (0.41; 10.7 [7.1–16.8] vs 4.2 [2.9–5.5]), but not QRSd (0.11; 155 [140–176] vs 167 [155–177] ms). TLVAT and SSI had a high predictive value for CRT response (AUC>0.80). TLVAT (OR=1.50), scar burden (0.91) and SSI (0.04) were independent factors associated with a positive response to CRT. Individuals with SSI >7.9% and TLVAT <91 ms all responded to CRT, while low SSI and prolonged TLVAT were more common in non-responders.

Conclusion

Electromechanical parameters show better correlation with CRT response than traditional surface ECG measurements. The absence of scar combined with high SSI and low TLVAT ensures effectiveness of CRT.

Funding Acknowledgement

Type of funding sources: Other. Main funding source(s): Swiss National Science Foundation, Statutory funds of the Medical University of Silesia
Acute hemodynamic effects of biventricular pacing studied during cardiovascular magnetic resonance imaging: the PICARIA Trial
Authors: Hopman L H G , Zweerink A , Van Der Lingen A C J , Mulder M J , Robbers L F H , Van Halm V P , Van Rossum A C , Gotte M J W , Allaart C P
Published: October 2022

Background

Cardiac resynchronization therapy (CRT) is hampered by a relative high rate of non-response whereby device optimization could aid in improving benefit from CRT. Nonetheless, a non-invasive and reproducible clinical tool for device optimization is currently lacking. Recently introduced cardiovascular magnetic resonance (CMR) compatible CRT devices may allow for patient follow-up and device optimization as biventricular (BIV) pacing can be performed during the CMR exam. However, to date, CMR evaluation of acute pump function changes during CRT is limited.

Purpose

To assess the effects of BIV-pacing on change in left ventricular (LV) function and contraction patterns using CMR.

Methods

Ten patients were included in this prospective pilot study. All patients underwent CMR imaging (1.5T system) prior to device implantation (baseline), and 6 weeks after device implantation (CRT-on and CRT-off). LV end systolic volume (ESV), end diastolic volume (EDV), ejection fraction (LVEF), and measures of LV dyssynchrony and dyscoordination (septal systolic rebound stretch (SRSseptal)) were assessed on cine images.

Results

LV function and contraction patterns before and after device implantation are compared and displayed in the figure. LV ESV and EDV decreased in all patients during BIV-pacing as compared to intrinsic rhythm (CRT-off) (ESV; 161.4±36.3ml vs. 194.9±37.1ml, p<0.01 and EDV; 236.2±31.8ml vs. 268.1±42.3ml, p<0.01). A significant improvement in LVEF was observed during BIV-pacing (32.2±8.7% vs. 27.4±5.9%, p<0.01). Both, regional dyssynchrony and regional dyscoordination significantly improved during CRT-on compared to CRT-off (peakseptal-peaklateral; 57±46ms vs. 183±86ms, p<0.01 and SRSseptal; 2.1±2.6% vs. 6.0±3.0%, p<0.01).

Conclusions

Post-CRT implantation CMR assessing acute pump function changes to different CRT pacing settings is feasible and provides important insights in the effects of BIV-pacing on cardiac function and contraction patterns. LV assessment using CMR, potentially in combination with non-invasive pressure measurements, may constitute a future CRT optimization strategy.

Funding Acknowledgement

Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Biotronik (Berlin, Germany)
Long-term outcome in patients with heart failure after cardiac surgery other than coronary artery bypass grafting treated with cardiac resynchronization therapy
Authors: Jedrzejczyk-Patej E , Mazurek M , Lenarczyk R , Sokal A , Kotalczyk A , Kowalska W , Gumprecht J , Kowalski O , Kalarus Z
Published: October 2022

Background

Cardiac resynchronization therapy (CRT) has been proven therapy in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). However, little is known about the prognosis, and the risk of cardiac device-related infective endocarditis (CDRIE) in patients with HF after cardiac surgery other than coronary artery bypass grafting (CABG) treated with CRT.

Aim

To assess the long-term outcome, mortality predictors, and the risk of CDRIE in patients with HF after cardiac surgery other than CABG treated with CRT.

Methods

The study population consisted of 1059 consecutive patients with CRT implanted between 2002 and 2019 in a tertiary care university hospital in a densely inhabited, urban region of Poland (949 subjects [89.6%] with CRT-D; 110 patients with CRT-P [10.4%]).

Results

The studied population was divided into two groups according to be or not after cardiac surgery other than CABG (n=74 patients [6.9%] vs. n=985 patients [93.1%]). During the median follow-up of 1661 days (10th and 90th percentile: 323–3995), all-cause mortality in patients after cardiac surgery other than CABG did not differ significantly in comparison to other CRT recipients (50% vs. 54.4%, P=0.46). Also, the risk of CDRIE was not statistically significant differ (2.7% vs. 5.7%, P=0.28). On multivariable regression analysis, only older age (HR 1.04, 95% CI 1.01–1.07, P=0.02) was identified as independent predictor of higher mortality in patients after cardiac surgery treated with CRT.

Kaplan-Meier curves of survival of patients after cardiac surgery other than CABG treated with cardiac resynchronization therapy in comparison to other CRT recipients are presented on Picture 1.

Conclusions

The mortality rate in patients after cardiac surgery other than CABG is similar to other subjects treated with CRT and reaches 50% within 4.5 years. The risk of device-related infective endocarditis is not higher than in other patients treated with CRT. Advanced age is an independent mortality predictor in subjects after cardiac surgery other than CABG undergoing CRT.

Funding Acknowledgement

Type of funding sources: None.
His-pacing and biventricular pacing show similar efficiency in resynchronization and improvements in longitudinal contractile function
Authors: Hoejgaard E V , Philbert B , Svendsen J H , Vinther M , Risum N
Published: October 2022

Background

The clinical role for HIS-pacing in cardiac resynchronization therapy (HIS-CRT) is promising but is yet to be established. The randomised His-alternative study showed better remodelling with HIS-CRT compared to patients receiving conventional biventricular pacing (BIV-CRT) in the per-protocol-analysis.

Purpose

In this substudy we investigated whether HIS-pacing was more efficient compared to BIV-CRT in improving mechanical synchrony and longitudinal contractile function.

Methods

In the His-Alternative study 50 patients with symptomatic heart failure, left ventricular ejection fraction (LVEF) ≤35% and Left bundle branch block were randomized 1:1 to His-CRT or BiV-CRT and followed for 6 months. At implantation, 7 patients crossed over from His-pacing to LV-pacing in the His-CRT group and 1 patient crossed over from LV-pacing to His-pacing in the BiV-CRT group. All patients had echocardiography performed including 2D-strain echocardiography to asses global systolic longitudinal deformation (GLS) at baseline and 6 months. Mechanical dyssynchrony was measured as SD of time-to-peak in all 12 segments of the left ventricle (TPS-SD).

Results

There were no significant differences in baseline characteristics between patients receiving HIS-CRT and BIV-CRT with regard to dyssynchrony and longitudinal systolic strain. LVEF was significantly higher at 6 months (48±8% vs. 42±8%; p<0.05) in the HIS-CRT group. However, GLS did not significantly improve more with HIS-CRT compared to BIV-CRT, (−8.7ms ± 2.0 to −11.1 ms ± 2.0 vs −9.1 ms ± 2.7 to −10.8±2.5 ms ± 2.8, P = ns for difference) and regarding resynchronization measured as TPS-SD there was no significant difference either (110 ms ± 51 to 47 ms ± 10 vs. 115 ms ± 42 to 60 ms ± 21, P = ns for difference).

Conclusion

In this substudy, HIS-pacing did not prove more efficient than BIV-CRT in resynchronizing the left ventricle, nor did the observed improvement in longitudinal function differ significantly between methods. However, the number of included patients was rather small and larger studies are needed to fully assess the possible benefits of HIS-CRT.

Funding Acknowledgement

Type of funding sources: None.
Long-term lead and mortality following pacemaker and defibrillator implantation in adult congenital heart disease
Authors: Stokes A , Karadakhy O , Lui C , Argyriou A , Almansoor Z , Adegboye O , Biswas S , Raj Krishna G , Agrawal D , Shah A , Kirkwood G , Morris G
Published: October 2022

Background

Adult congenital heart disease (ACHD) survival has dramatically improved in recent decades. As such, clinicians now face the complex long-term interactions of congenital and chronic heart diseases. One area of continuing mortality in this group is arrhythmias, especially in those with cardiovascular implantable electronic devices (CIEDs). With these developments in survival, the long-term outcomes of the CIED systems and their effects on mortality are beginning to be elucidated.

Aims

This study aims to compare the effects of system location, surgical history, patient demographics and congenital disease complexity on lead survival, complication distributions and patient mortality in ACHD CIED patients.

Methods

A retrospective cohort of 250 ACHD CIED patients with follow up at a heart centre was collated from clinical correspondence letters and CEID records. Data was collected on demographics, mortality and lead survival and complications. Survival data was analysed with Kaplan-Meier (KM) curves and hazard ratio tests.

Results

Complex ADHD patient survival was less than the non-complex cohort (HR 0.38, 95% CI 0.22–0.67, p<0.01). Lead survival was longer in non-surgical patients (HR 1.42, 95% CI 1.13–1.78, p<0.01) and longer in female patients (HR 1.35, 95% CI 1.07–1.69, p<0.01) (Figure 1). No significant differences in mortality or lead survival were seen between epicardial and transvenous systems.

Conclusions

Complex ACHD is associated with worse patient mortality in CEID patients. Surgical history and male gender are associated with worsened lead survival.

Funding Acknowledgement

Type of funding sources: None.
Transvenous removal of pacing and ICD leads: single Italian referral center experience
Authors: Segreti L , Fiorentini F , Giannotti Santoro M , Barletta V , Di Cori A , Viani S , De Lucia R , Grifoni G , Paperini L , Soldati E , Cellamaro T , Carluccio M , Branchitta G , Zucchelli G , Bongiorni M G
Published: October 2022

Introduction

Device related complications are rising the need of Transvenous Lead Removal (TLR). Transvenous extraction of Pacing (PL) and Defibrillating Leads (DL) is a highly effective technique. Aim of this report is to analyse the longstanding experience performed in a single Italian Referral Center.

Methods

From January 1997 to December 2021, we managed 2925 consecutive patients (2220 men, mean age 65.3 years) with 5370 leads (mean dwell time 74.0 months, range 1–576). PL were 4209 (1903 ventricular, 1801 atrial, 505 coronary sinus leads), DL were 1161 (1140 ventricular, 6 atrial, 15 superior vena cava leads). Indications to TLR were infection in 78% (systemic 27%, local 51%) of leads. We performed mechanical dilatation using a single polypropylene sheath technique and, if necessary, other intravascular tools; we performed an approach through the Internal Jugular Vein (JA) in case of free-floating leads or failure of the standard approach.

Results

We attempted removal in 5359 leads because the technique was not applicable in 11 PL. Among these, 5223 leads were completely removed (97.4%), 51 (1.0%) were partially removed, 85 (1.6%) were not removed. Among 5271 exposed leads: manual traction removed 879 (16.7%) leads; mechanical dilatation using the venous entry site removed 3860 (73.2%) leads; femoral approach (FA) removed 50 (0.9%) leads; and JA removed 346 (6.6%) leads. All the free-floating leads were completely removed, 26.1% by FA and 73.9% by JA. Major complications occurred in 23 cases (0.78%): cardiac tamponade (21 cases, 5 deaths), hemothorax (2 cases, 1 death).

Conclusions

Our experience shows that in centers with wide experience, TLR using single sheath mechanical dilatation has a high success rate and a very low incidence of serious complications. TLR through the Internal Jugular Vein increases the effectiveness and safety of the procedure also in case of free-floating or challenging leads.

Funding Acknowledgement

Type of funding sources: None.
Risk of lead explantation after first-time implantation of cardiac implantable electronic device as a function of comorbidity: a nationwide study
Authors: Alhakak A , Philbert B T , Risum N , Mogensen U M , Jons C , Jacobsen P K , Haarbo J , Johansen J B , Nielsen J C , Riahi S , Torp-Pedersen C , Fosbol E L , Kober L , Vinther M , Weeke P E
Published: October 2022

Background

The benefit of cardiac implantable electronic devices (CIEDs) is challenged by the risk of procedure-related complications and lead explantation. Whether patient comorbidity burden is associated with risk of lead explantation <6 months of implantation is unknown.

Purpose

We assessed the risk of lead explantation and its association with comorbidity burden within 6 months after first-time CIED implantation.

Methods

The study population comprised patients ≥18 years old with first-time CIED implantation (i.e., pacemaker [PM], implantable cardioverter defibrillator [ICD], and cardiac resynchronisation therapy with defibrillator [CRT-D] or without [CRT-P]) using Danish nationwide registries including the Danish Pacemaker and ICD registry (1 January 2000 to 30 June 2018). Patients were followed from their first-time CIED implantation and 6 months forward. Patient comorbidity burden was categorised in four groups according to the Charlson Comorbidity Index (CCI) score: 0 (none), 1–2 (mild), 3–4 (moderate), and ≥5 (severe). Multivariable cause-specific Cox regression was performed to assess risk of lead explantation according to comorbidity burden, with death as competing risk. Comorbidity burden was adjusted for sex, age, type of CIED, and body mass index categories.

Results

We identified 73,491 patients with first-time CIED implantation including 55,733 (75.8%) with PM, 11,351 (15.5%) with ICD, 2,989 (4.1%) with CRT-P, and 3,418 (4.7%) with CRT-D. In total, 1,049 (1.4%) patients underwent lead explantation. The median age of the study population was 75.1 years [25th-75th percentile 66.2–82.5 years], and 62.1% were male. Patients undergoing lead explantation had higher median CCI score, compared with those not undergoing lead explantation (2 [1–3] and 1 [0–3], respectively). The median age and distribution of sex were similar in both groups. In the multivariable Cox regression model (Figure 1), an increase in patient comorbidity burden was associated with higher hazard ratio [HR] of lead explantation, compared with CCI score 0 (CCI score 1–2: HR=1.38 [95% confidence interval [CI]: 1.12–1.69], CCI score 3–4: HR=1.61 [95% CI: 1.28–2.03], and CCI score ≥5: HR=1.60 [95% CI: 1.25–2.05]).

Conclusion

Risk of lead explantation within 6 months after first-time implantation of cardiac implantable electronic device was 1.4% and associated with higher comorbidity burden.

Funding Acknowledgement

Type of funding sources: Foundation. Main funding source(s): Independent Research Fund Denmark
The impact of ventricular-arterial coupling on aerobic capacity across the heart failure spectrum
Authors: Pugliese N R , Balletti A , Armenia S , De Biase N , Faita F , Mengozzi A , Paneni F , Ruschitzka F , Virdis A , Ghiadoni L , Taddei S , Williams B , Antonini-Canterin F , Masi S
Published: October 2022

Background

Ventricular-arterial coupling (VAC) can be evaluated as the ratio between arterial stiffness (pulse wave velocity, PWV) and myocardial deformation (global longitudinal strain, GLS).

Objectives

To evaluate VAC across the spectrum of heart failure (HF).

Methods

We introduced a Doppler-derived, single-beat technique to estimate aortic arch PWV (aa-PWV) in addition to tonometry-derived carotid-femoral PWV (cf-PWV). We measured PWVs and 3D-GLS in 155 healthy controls, 75 subjects at risk of developing HF (American College of Cardiology/American Heart Association Stage A-B) and 236 patients in HF Stage C with preserved (HFpEF, n=104) or reduced ejection fraction (HFrEF, n=132). We evaluated peak oxygen consumption (VO2) and peripheral extraction (AVO2diff) using combined cardiopulmonary-echocardiography exercise stress.

Results

aa-PWV was obtainable in all subjects and significantly lower than cf-PWV in all subgroups (p<0.01). PWVs were directly related and increased with age (all p<0.0001). cf-PWV/3D-GLS was similarly compromised in HFrEF (1.08±0.36) and HFpEF (1.05±0.22), while aa-PWV/3D-GLS was more impaired in HFpEF (0.69±0.11) than HFrEF (0.60±0.15; p<0.01). Stage A-B had values of cf-PWV/3D-GLS and aa-PWV/3D-GLS (0.66±0.25 and 0.47±0.12) higher than controls (0.47±0.10 and 0.40±0.10) but lower than Stage C (all p<0.01). Peak AVO2diff was inversely related with cf-PWV/3D-GLS and aa-PWV/3D-GLS (all p<0.01). cf-PWV/3D-GLS and aa-PWV/3D-GLS independently predicted peak VO2 in the overall population (adjusted R2=0.32 and 0.35; all p<0.0001) but only aa-PWV/3D-GLS was independently associated with flow reserve during exercise (R2=0.51; p<0.0001).

Conclusion

Abnormal VAC is directly correlated with greater severity of HF and worse functional capacity. HFpEF shows a worse VAC than HFrEF when expressed by aa-PWV/3D-GLS.

Funding Acknowledgement

Type of funding sources: None.
Biomarker profiles and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome
Authors: Van Der Hoef C C S , Boorsma E M , Emmens J E , Mordi I R , Dihoum A , Lang C C , Voors A A
Published: October 2022

Introduction

The risk factors that collectively define metabolic syndrome (MetS) are common in heart failure (HF) patients. More research is needed to elucidate the individual role of MetS in the pathophysiology of HF.

Purpose

The study investigates the differences in biomarker profiles of HF patients with MetS and without MetS.

Methods and results

The prevalence of MetS was 468 of the 1103 patients (42.4%) in the index cohort and 615 of 1433 (42.9%) patients in the validation cohort. With a microarray analysis of 363 biomarkers, the biomarker profiles of HF patients with versus without MetS were identified. The resulting biomarker profiles were used in network analysis to analyse the underlying pathophysiological mechanisms. The biomarker profile for MetS showed 43 upregulated and 5 downregulated biomarkers in the index cohort. In the validation cohort, there were 58 upregulated and 3 downregulated biomarkers. The most significantly upregulated biomarkers shared between the two cohorts were leptin, fatty acid-binding protein 4, interleukin-1 receptor antagonist, tumour necrosis factor receptor superfamily member 11a, and RET proto-oncogene. Network analysis identified 10 pathways in the index cohort and 6 in the validation cohort, all related to inflammation.

Conclusion

Pathophysiological pathways leading to HF in patients with MetS are most likely related to obesity and the chronic inflammatory state found in these patients. The role of obesity in the pathophysiology of HF should be validated in similar research to analyse and compare the outcomes. Several individual proteins were identified that might be interesting targets for future research and new treatment options for HF patients.

Funding Acknowledgement

Type of funding sources: None.